AstraZeneca announced that its COVID-19 vaccine candidate developed at the University of Oxford was well-tolerated in clinical trials in Brazil and the UK and was 90% effective in participants given a half-dose followed a month later by a full dose. The vaccine was 62% effective when given as two full doses, and it is likely to cost less than mRNA-based vaccines developed by Moderna and Pfizer/BioNTech, and the AstraZeneca vaccine does not require storage at subzero temperatures.
AstraZeneca/Oxford vaccine 90% effective in study
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.